Stocks and Investing
Stocks and Investing
Thu, March 11, 2021
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Michelle Gilson Maintained (STOK) at Strong Buy with Increased Target to $76 on, Mar 11th, 2021
Michelle Gilson of Canaccord Genuity, Maintained "Stoke Therapeutics, Inc." (STOK) at Strong Buy with Increased Target from $72 to $76 on, Mar 11th, 2021.
Michelle has made no other calls on STOK in the last 4 months.
There are 3 other peers that have a rating on STOK. Out of the 3 peers that are also analyzing STOK, 1 agrees with Michelle's Rating of Hold. Following is the relevant analyst calls for the last 4 months
- Laura Chico of "Wedbush" Downgraded from Buy to Hold on, Wednesday, February 10th, 2021
These are the ratings of the 2 analyists that currently disagree with Michelle
- Martin Auster of "Credit Suisse" Maintained at Buy with Increased Target to $58 on, Wednesday, March 10th, 2021
- Joseph Stringer of "Needham" Maintained at Strong Buy with Increased Target to $65 on, Thursday, January 14th, 2021
Contributing Sources